Labcorp and Fox Chase Cancer Center are collaborating on a clinical trial using the Plasma Detect test for molecular monitoring in non-small cell lung cancer (NSCLC). The study will test patients with stage IB–IIIA disease undergoing surgery, comparing Plasma Detect results against conventional imaging-based monitoring. The Plasma Detect approach targets circulating tumor DNA and other tumor signals to support earlier detection of recurrence compared with standard radiographic follow-up. The trial design is aimed at benchmarking performance across surgical-stage patients where long-term surveillance decisions are critical. For the broader oncology diagnostics ecosystem, the partnership reinforces the shift toward blood-based MRD and recurrence monitoring in settings traditionally driven by CT scans. If successful, it could inform future label expansions and payer discussions. The next focus will be whether molecular results correlate with clinical outcomes such as recurrence timing and whether the assay can reduce the intensity or frequency of imaging without compromising detection.